Wasan K M, Lopez-Berestein G
Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada.
Clin Infect Dis. 1996 Nov;23(5):1126-38. doi: 10.1093/clinids/23.5.1126.
Patients with cancer and infectious diseases often have changes in the composition and concentration of their different blood components. These changes include variations in the composition and concentration of plasma lipoprotein lipids, in transfer rates of endogenous lipid between different lipoprotein classes, and in concentrations of phagocytic cells (i.e., monocytes and macrophages). It appears that the interaction of many lipid-based drug formulations with plasma lipoproteins and blood phagocytic cells may be responsible for the unpredictable pharmacokinetics and pharmacodynamics of those compounds when administered to patients with diseases. This review examines the potential mechanisms that may explain the biological behavior of lipid-based drug formulations used in the treatment of infectious diseases and cancer.
患有癌症和传染病的患者,其不同血液成分的组成和浓度常常会发生变化。这些变化包括血浆脂蛋白脂质的组成和浓度变化、内源性脂质在不同脂蛋白类别之间的转运速率变化,以及吞噬细胞(即单核细胞和巨噬细胞)的浓度变化。许多基于脂质的药物制剂与血浆脂蛋白和血液吞噬细胞之间的相互作用,可能是这些化合物在给患有疾病的患者给药时药代动力学和药效学不可预测的原因。本综述探讨了可能解释用于治疗传染病和癌症的基于脂质的药物制剂生物学行为的潜在机制。